Lantern Pharma rises on FDA guidance for cancer drug trials
17/01/2023 13:51
** Shares of drug developer Lantern Pharma Inc LTRN.O
rise 4% premarket to $5.7
** Co receives guidance from FDA on clinical development
plans for its drug candidate targeting a range of cancers
including solid tumors and central nervous system cancers
** FDA feedback clears path for submission of clinical study
application and initiation of human trials in Q2 2023 - LTRN
** Stock has declined 25.8% in last 12 months
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments